Kiniksa Pharmaceuticals International PLC
(NAS:KNSA)
$
74.34
-3.84 (-4.91%)
Market Cap: 5.80 Bil
Enterprise Value: 5.28 Bil
PE Ratio: 76.64
PB Ratio: 8.86
GF Score: 46/100 Kiniksa Pharmaceuticals Ltd at Bank of America Biotech SMID Cap Conference Transcript
Dec 07, 2022 / 03:15PM GMT
Release Date Price:
$15.34
(-0.13%)
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
Okay. Good morning. Welcome to the BofA SMID Cap Biotech Conference. My name is Geoff Meacham, I'm the Senior of Biopharma analyst, and welcome to the morning sessions. We're thrilled to have with us Kiniksa. Speaking on behalf of Kiniksa is CEO, Sanj Patel. Sanj, how are you?
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst
I'm fairly well, how are you, Geoff?
Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst
Good. Good to see your face. Next year, maybe we'll do this in person. So let's just kick it off real quick. I know you're an efficient guy, so let's just go and give us a 30,000-foot view here of a quick background and then get right into some questions on our (inaudible) a lot of stuff.
Sanj K. Patel
Kiniksa Pharmaceuticals, Ltd. - CEO & Chairman of the Board
Absolutely. So again, thanks for having me here, Geoff.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot